Showing results (91-100 of 106) with videos related to
Sort By:
Pageof 11
The Journal of Urology|January 11, 2023
Pathological and Clinical Outcomes in a Large Surveillance and Intervention Cohort of Radiographically Cystic Renal MassesRandall A Lee, Robert G Uzzo, Jordan Anaokar, et al.The Journal of Urology|April 7, 2020
Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II TrialDaniel M Geynisman, Brian T Kadow, Brian M Shuch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2024
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)Daniel M Geynisman, Philip H Abbosh, Eric Ross, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2014
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicityElizabeth R Plimack, Jean H Hoffman-Censits, Rosalia Viterbo, et al.European Urology Oncology|November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 TrialFern Anari, John O'Neill, Woonyoung Choi, et al.European Urology|August 5, 2015
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerElizabeth R Plimack, Roland L Dunbrack, Timothy A Brennan, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2013
Penile cancer: Clinical Practice Guidelines in OncologyPeter E Clark, Philippe E Spiess, Neeraj Agarwal, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2013
Bladder cancerPeter E Clark, Neeraj Agarwal, Matthew C Biagioli, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2016
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157Noah M Hahn, Trinity J Bivalacqua, Ashley E Ross, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyThomas W Flaig, Philippe E Spiess, Neeraj Agarwal, et al.Pageof 11